UNICA IRIS Institutional Research Information System

MULAS, OLGA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 337.109
NA - Nord America 1.926
AS - Asia 517
SA - Sud America 16
AF - Africa 7
OC - Oceania 1
Totale 339.576
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 336.578
US - Stati Uniti d'America 1.916
CN - Cina 244
SE - Svezia 215
SG - Singapore 116
DE - Germania 89
KR - Corea 78
FI - Finlandia 77
UA - Ucraina 58
GB - Regno Unito 30
IN - India 21
VN - Vietnam 16
PL - Polonia 13
HK - Hong Kong 11
CA - Canada 10
CZ - Repubblica Ceca 10
BR - Brasile 8
FR - Francia 8
IR - Iran 8
JO - Giordania 5
AR - Argentina 4
AT - Austria 4
ID - Indonesia 4
IE - Irlanda 4
PH - Filippine 4
BE - Belgio 3
ES - Italia 3
JP - Giappone 3
NL - Olanda 3
RU - Federazione Russa 3
BO - Bolivia 2
CH - Svizzera 2
EC - Ecuador 2
EG - Egitto 2
HU - Ungheria 2
IQ - Iraq 2
MA - Marocco 2
RO - Romania 2
TR - Turchia 2
BF - Burkina Faso 1
BG - Bulgaria 1
CI - Costa d'Avorio 1
CY - Cipro 1
HR - Croazia 1
LU - Lussemburgo 1
MY - Malesia 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PK - Pakistan 1
SK - Slovacchia (Repubblica Slovacca) 1
ZA - Sudafrica 1
Totale 339.576
Salva come PNG Salva come JPEG
Città #
Cagliari 314.233
Uta 21.872
Fairfield 231
Boardman 198
Ashburn 165
Nyköping 145
Woodbridge 134
Chandler 123
Seattle 115
Houston 110
Cambridge 102
New York 94
Wilmington 93
Shanghai 81
Helsinki 66
Santa Clara 65
Ann Arbor 64
Rome 61
Singapore 59
Seoul 44
Milan 37
Beijing 34
Incheon 33
Boston 27
Dearborn 21
Los Angeles 21
San Diego 20
Jacksonville 19
Dong Ket 16
Redwood City 15
Nanjing 12
Krefeld 11
Munich 11
Bologna 10
London 10
Atlanta 9
Guangzhou 9
Warsaw 9
Hong Kong 8
Mountain View 8
Naples 8
Rio de Janeiro 8
Turin 8
Alghero 7
Olomouc 7
Pune 7
Redmond 7
Toronto 7
Berlin 6
Lappeenranta 6
Padova 6
Quartu Sant'Elena 6
Amman 5
Borghetto di Borbera 5
Changsha 5
Detroit 5
Elmas 5
Gonnesa 5
Nanchang 5
Wuhan 5
Bad Bellingen 4
Biella 4
Buenos Aires 4
Dublin 4
Florence 4
Fuzhou 4
Macomer 4
Miano 4
Norwalk 4
Ragusa 4
San Mateo 4
Umeå 4
Washington 4
Brescia 3
Brussels 3
Certaldo 3
Council Bluffs 3
Genoa 3
Hefei 3
Jiaxing 3
Manta 3
Messina 3
Nuoro 3
Palermo 3
Shenzhen 3
Sorso 3
Tianjin 3
Trentola-Ducenta 3
Venezia 3
Vienna 3
Zhengzhou 3
Acton 2
Alcamo 2
Amsterdam 2
Andover 2
Arbus 2
Bari 2
Berchidda 2
Borås 2
Brno 2
Totale 338.642
Salva come PNG Salva come JPEG
Nome #
Patient-Physician Communication in Acute Myeloid Leukemia and Myelodysplastic Syndrome 240.331
Infectious Complications in Autoimmune Hemolytic Anemia: A Multi-Center Italian Experience 33.593
Association of Hypometilating Agents (HMA) plus Venetoclax (VEN) in the Treatment of Myeloproliferative Neoplasms in Blastic Phase (MPN-BP) and Acute Leukemias Evolved from Myelodysplastic Syndromes (AML-MDS) Already Treated with Azacytidine 3.357
Killer immunoglobulin-like receptors can predict TKI treatment-free remission in chronic myeloid leukemia patients 3.242
Metabolomics Profile of Patients with Chronic Myeloid Leukemia and Cardiovascular Adverse Events after Treatment with Tyrosine Kinase Inhibitors 3.184
Homozygosity for killer immunoglobin-like receptor haplotype A predicts complete molecular response to treatment with tyrosine kinase inhibitors in chronic myeloid leukemia patients 3.170
HLA-G molecules and clinical outcome in Chronic Myeloid Leukemia 3.086
Permanent Discontinuation of Tyrosine Kinase Inhibitor Frontline Therapy in Patients with Chronic Phase Chronic Myeloid Leukemia Patients during the First 36 Months of Treatment: A "Campus CML" Study 2.803
Kir haplotype aa is a possible predictive marker of complete molecular response to tyrosine kinase inhibitors in patients with chronic myeloid leukemia 2.671
Ruolo del trapianto allogenico nelle talassemie 2.578
Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart 2.505
Favourable outcome of chronic myeloid leukemia co-expressing e13a2 and e14a2 transcripts, treated with nilotinib 2.089
Metabolomic Analysis of Patients with Chronic Myeloid Leukemia and Cardiovascular Adverse Events after Treatment with Tyrosine Kinase Inhibitors 2.059
Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary prevention 2.003
Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis 1.996
Rituximab Monotherapy or in Combination with Bendamustine Is Not Inferior to Rituximab-CHOP Regimen in the Treatment of Patients with Splenic Marginal Zone Lymphoma in the Real Life 1.847
Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice 1.805
Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors 1.729
Residual peripheral blood CD26+leukemic stem cells in chronic myeloid leukemia patients during TKI therapy and during treatment-free remission 1.705
Increased incidence of infection in patients with myelofibrosis and transfusion-associated iron overload in the clinical setting 1.554
Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors 1.475
Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib 1.411
Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study 1.384
The association between Major Depressive Disorder and premature death risk in hematologic and solid cancer: a longitudinal cohort study 878
Thyroid autoimmunity and hypothyroidism are associated with deep molecular response in patients with chronic myeloid leukemia on tyrosine kinase inhibitors 832
Dihydroorotate dehydrogenase inhibition reveals metabolic vulnerability in chronic myeloid leukemia 816
Conditioning Regimens in Patients with β-Thalassemia Who Underwent Hematopoietic Stem Cell Transplantation: A Scoping Review 748
Risk and Response-Adapted Treatment in Multiple Myeloma 747
Arterial Hypertension and Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Systematic Review and Meta-Analysis 733
Health-related quality of life profile of patients with immune thrombocytopenia in the real life is impaired by splenectomy 720
Safety and efficacy of caplacizumab retreatment in a real-life monocentric cohort of patients with immune-mediated thrombotic thrombocytopenic purpura 702
Ruxolitinib does not impair humoral immune response to COVID-19 vaccination with BNT162b2 mRNA COVID-19 vaccine in patients with myelofibrosis 695
Health-Related Quality of Life Assessment in Patients with Myelodysplastic Syndromes: Evidence from Randomized Clinical Trials 612
Health-Related Quality-of-Life Profile of Pediatric Patients with β Thalassemia after Hematopoietic Stem Cell Transplantation 588
Long-term health-related quality of life in patients with beta-thalassemia after unrelated hematopoietic stem cell transplantation 543
Analysis of Early Events during the First Year of Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Phase - Chronic Myeloid Leukemia: A "Campus CML" Study 489
Patients with Chronic Lymphocytic Leukemia Have a Very High Risk of Ineffective Response to the BNT162b2 Vaccine 487
Should be a Third Dose of BNT162b2 mRNA COVID-19-Vaccine Administered in Patients with Myelofibrosis Under Ruxolitinib? 486
The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib 476
Safety and Efficacy of TKIs in very Elderly Patients (≥75 Years) with Chronic Myeloid Leukemia 465
Prognostic Role of Cell Blood Count in Chronic Myeloid Neoplasm and Acute Myeloid Leukemia and Its Possible Implications in Hematopoietic Stem Cell Transplantation 457
Chronic graft vs. host disease and hypogammaglobulinemia predict a lower immunological response to the BNT162b2 mRNA COVID-19 vaccine after allogeneic hematopoietic stem cell transplantation 453
Renin-angiotensin inhibitors reduce thrombotic complications in Essential Thrombocythemia and Polycythemia Vera patients with arterial hypertension 447
Low adherence to therapy and co-morbid depressive episodes are independent determinants of early death in people with cancer 428
Pathogenic and Prognostic Roles of Paraneoplastic Leukocytosis in Cervical Cancer: Can Genomic-Based Targeted Therapies Have a Role? A Literature Review and an Emblematic Case Report 406
CML-164 Dihydroorotate Dehydrogenase Inhibition Reveals Metabolic Vulnerability in Chronic Myeloid Leukemia 404
Prognostic Factors for Overall Survival In Chronic Myeloid Leukemia Patients: A Multicentric Cohort Study by the Italian CML GIMEMA Network 372
Adherence to treatment in patients with solid and hematological cancers. Could spiritual and psychological support facilitate optimal adherence? 359
Long-Term Health-Related Quality of Life and Clinical Outcomes in Patients with β-Thalassemia after Splenectomy 357
Systematic Review and Meta-Analysis of Health-Related Quality of Life in Patients with β-Thalassemia Underwent Hematopoietic Stem Cell Transplantation 351
Determinants of frontline tyrosine kinase inhibitor choice for patients with chronic-phase chronic myeloid leukemia: A study from the Registro Italiano LMC and Campus CML 341
Pro-Inflammatory and Pro-Oxidative Changes During Nilotinib Treatment in CML Patients: Results of a Prospective Multicenter Front-Line TKIs Study (KIARO Study) 340
On the Children Side. Overview of 194 Outcomes from Gimema Registry of Conception/Pregnancy in Chronic Myeloid Leukemia (CML) 324
Extracellular vesicles in the Chronic Myeloid Leukemia scenario: an update about the shuttling of disease markers and therapeutic molecules 305
Understanding the user's point of view: when the doctor gets sick with cancer and seeks help 298
Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the “RAMP” Italian multicenter prospective study 268
Patients' Perception of Usability and Utility of a Digital Health Tool for Electronic Patient-Reported Outcomes Monitoring in Real-Life Hematology Practice: Evidence from the Gimema-Alliance Platform 265
The Direct and Indirect Effects of Tyrosine Kinase Inhibitors on the Cardiovascular System in Chronic Myeloid Leukemia 254
Association of Hypomethylating Agents + Venetoclax in the Real-Life Treatment of Myeloproliferative Neoplasms in Blastic Phase 202
Increase of Arterial Stiffness in Patients with Polycythemia Vera 185
Long-term health-related quality of life and mental health in patients with immune thrombotic thrombocytopenic purpura 150
Thrombotic and Infectious Complications in Patients with Autoimmune Hemolytic Anemia: A Multicenter Observational Study 139
Response to Dr. Ying Cui comments 101
Arterial Stiffness as a New Predictor of Clinical Outcome in Patients with Polycythemia Vera 7
Totale 339.807
Salva come PNG Salva come JPEG
Categoria #
all - tutte 356.048
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 356.048
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20205.434 0 0 0 0 1.960 1.629 894 212 153 155 149 282
2020/202113.973 345 643 592 3.787 2.426 1.582 945 886 376 1.043 848 500
2021/20225.564 448 372 235 320 437 382 265 281 533 736 903 652
2022/20237.277 430 861 931 581 539 826 413 599 506 521 712 358
2023/20248.692 389 300 383 540 675 1.558 1.186 666 556 612 866 961
2024/2025294.276 9.454 105.120 175.909 2.949 844 0 0 0 0 0 0 0
Totale 339.807